Upcoming Nsclc Trials In 2022: Checkmate 816 & Keynote-091

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies - Lung Cancer OncTalk 2022

GRACE - Global Resource for Advancing Cancer Education

CheckMate 816: what does the data tell us?

Surgical outcomes from the Phase III CheckMate 816 trial

Event-free survival results from CheckMate 816

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023

GRACE - Global Resource for Advancing Cancer Education

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLC

GRACE - Global Resource for Advancing Cancer Education

Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022

European Society for Medical Oncology (ESMO)

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC

European Society for Medical Oncology (ESMO)

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IO

Immunotherapy as combination and neoadjuvant therapies in NSCLC

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022

GRACE - Global Resource for Advancing Cancer Education

Perioperative therapies in NSCLC

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...

Future directions for neoadjuvant immunotherapy in lung cancer

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

The rationale and trial design of the NADIM II trial

Dr. Porter on the 3-Year Follow-Up Data From the CheckMate-9LA Trial in NSCLC